Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 2,932 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 2,932 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64. Following the completion of the sale, the chief executive officer owned 44,525 shares in the company, valued at approximately $1,781,890.50. This trade represents a 6.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total transaction of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total value of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total value of $232,425.60.

Phibro Animal Health Stock Performance

PAHC stock opened at $40.06 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $46.42. The business has a 50-day moving average price of $40.65 and a 200 day moving average price of $36.92. The company has a market capitalization of $1.62 billion, a P/E ratio of 24.13, a PEG ratio of 1.13 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The business had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were given a $0.12 dividend. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio is currently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of PAHC. Capricorn Fund Managers Ltd acquired a new stake in Phibro Animal Health in the 3rd quarter valued at approximately $10,233,000. JPMorgan Chase & Co. boosted its holdings in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after purchasing an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Phibro Animal Health in the third quarter valued at $8,931,000. Ranger Investment Management L.P. grew its holdings in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after purchasing an additional 179,975 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PAHC has been the subject of several recent analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. JPMorgan Chase & Co. raised their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and an average target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.